阿帕替尼联合替吉奥胶囊三线治疗晚期结直肠癌的疗效

Efficacy of apatinib mesylate combined with TS-1 capsules as third-line treatment of advanced colorectal cancer

目的评价阿帕替尼联合替吉奥胶囊三线治疗晚期结直肠癌的疗效与安全性。方法选取13例晚期结直肠癌三线治疗患者,给予阿帕替尼联合替吉奥治疗,每治疗两个周期后按实体瘤疗效评价标准(RECIST)评价疗效,同时按常见不良反应事件评价标准(CTCAE)评价安全性。结果13例患者中,部分缓解2例,稳定5例,进展6例,中位疾病进展时间92.9d。不良反应主要为乏力、高血压、中性粒细胞减少、手足综合征及黏膜炎,多为Ⅰ、Ⅱ级。结论阿帕替尼联合替吉奥胶囊三线治疗晚期结直肠癌的临床效果较好,不良反应轻微。

Objective To evaluate the efficacy and safety of apatinib mesylate combined with tegafur,gimeracil and oteracil potassium（TS-1）capsules as the third-line treatment of advanced colorectal cancer.Methods Thirteen patients with advanced colorectal cancer received apatinib mesylate combined with TS-1 capsules as the third-line treatment.After every two cycles,therapeutic efficacy was evaluated according to RECIST version 1.1.Adverse effects were assessed during treatment according to CTCAE version 4.0.Results Of 13 patients,2 patients had partial responses,5 patients had stable diseases and 6 patients had progressive diseases.The median time disease progression was 92.9 days.The mainly adverse effects were fatigue,hypertension,neutropenia,handfoot syndrome and mucositis,which were grade 1-2 mostly.Conclusion Apatinib mesylate combined with TS-1 capsules as the third-line treatment for the patients with advanced colorectal cancer has the advantages of good efficacy and mild adverse effects.